Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus

被引：109

作者：

Wolter, N

Smith, AM

Farrell, DJ

Schaffner, W

Moore, M

Whitney, CG

Jorgensen, JH

Klugman, KP

机构：

[1] Natl Inst Communicable Dis, Resp & Meningeal Pathogens Res Unit, MRC, NICD,WITS, ZA-2000 Johannesburg, South Africa

[2] Univ Witwatersrand, Johannesburg, South Africa

[3] GR Micro Ltd, London, England

[4] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN USA

[5] Ctr Dis Control & Prevent, Div Bact & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA USA

[6] Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78285 USA

[7] Emory Univ, Sch Med, Rollins Sch Publ Hlth, Dept Global Hlth, Atlanta, GA 30322 USA

[8] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA 30322 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2005年 / 49卷 / 08期

关键词：

D O I：

10.1128/AAC.49.8.3554-3557.2005

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Two clinical Streptococcus pneumoniae isolates, identified as resistant to macrolides and chloramphenicol and nonsusceptible to linezolid, were found to contain 6-bp deletions in the gene encoding riboprotein L4. The gene transformed susceptible strain R6 so that it exhibited such resistance, with the transformants also showing a fitness cost. We demonstrate a novel bacterial mechanism of resistance to chloramphenicol and nonsusceptibility to linezolid.

引用

页码：3554 / 3557

页数：4

共 35 条

[1]

[Anonymous], 2003, NCCLS Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, V6th

[2] Emergence of group a streptococcus strains with different mechanisms of macrolide resistance [J].

Bingen, E ;

Leclercq, R ;

Fitoussi, F ;

Brahimi, N ;

Malbruny, B ;

Deforche, D ;

Cohen, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (05) :1199-1203

[3] Development of macrolide resistance by ribosomal protein L4 mutation in Streptococcus pyogenes during miocamycin treatment of an eight-year-old Greek child with tonsillopharyngitis [J].

Bozdogan, B ;

Appelbaum, PC ;

Ednie, L ;

Grivea, IN ;

Syrogiannopoulos, GA .

CLINICAL MICROBIOLOGY AND INFECTION, 2003, 9 (09) :966-969

[4]

DANGVAN A, 1978, ANTIMICROB AGENTS CH, V13, P557

[5] Linezolid-resistant Enterococcus faecalis isolated from a cord blood transplant recipient [J].

Dibo, I ;

Pillai, SK ;

Gold, HS ;

Baer, MR ;

Wetzler, M ;

Slack, JL ;

Hazamy, PA ;

Ball, D ;

Bin Hsiao, C ;

McCarthy, PL ;

Segal, BH .

JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (04) :1843-1845

[6] A multilocus sequence typing scheme for Streptococcus pneumoniae:: identification of clones associated with serious invasive disease [J].

Enright, MC ;

Spratt, BG .

MICROBIOLOGY-UK, 1998, 144 :3049-3060

[7] In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations [J].

Farrell, DJ ;

Morrissey, I ;

Bakker, S ;

Buckridge, S ;

Felmingham, D .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (08) :3169-3171

[8] Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study [J].

Farrell, DJ ;

Douthwaite, S ;

Morrissey, I ;

Bakker, S ;

Poehlsgaard, J ;

Jakobsen, L ;

Felmingham, D .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (06) :1777-1783

[9] The polypeptide tunnel system in the ribosome and its gating in erythromycin resistance mutants of L4 and L22 [J].

Gabashvili, IS ;

Gregory, ST ;

Valle, M ;

Grassucci, R ;

Worbs, M ;

Wahl, MC ;

Dahlberg, AE ;

Frank, J .

MOLECULAR CELL, 2001, 8 (01) :181-188

[10] Clonal distribution of invasive pneumococcal isolates from children and selected adults in the United States prior to 7-valent conjugate vaccine introduction [J].

Gertz, RE ;

McEllistrem, MC ;

Boxrud, DJ ;

Li, ZY ;

Sakota, V ;

Thompson, TA ;

Facklam, RR ;

Besser, JM ;

Harrison, LH ;

Whitney, CG ;

Beall, B .

JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (09) :4194-4216

← 1 2 3 4 →